Physician profile
Robert Sepulveda
NPI 1366473258
$3,591.64
in general payments reported to CMS, 2019-2025
16 companies · $1,073 in 2025
The $1,073 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2023: $1,004 · 2024: $1,358 · 2025: $1,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,435.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $672.42 | 2023-2025 | Freestyle Libre 3, Freestyle Libre |
| Novo Nordisk INC | $579.11 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $543.98 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $396.66 | 2023-2025 | |
| Amgen INC. | $358.27 | 2023-2025 | Repatha, Prolia, Otezla |
| Janssen Pharmaceuticals, INC | $194.82 | 2019-2024 | Xarelto |
| Abbvie INC. | $190.01 | 2023-2024 | Qulipta, Vraylar |
| Allergan, INC. | $125.00 | 2019 | |
| Pfizer INC. | $123.02 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $115.42 | 2025 | Rexulti |
| Exact Sciences Corporation | $83.00 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $76.76 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $62.48 | 2023-2024 | Farxiga, Airsupra |
| Dexcom, INC. | $34.32 | 2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $18.56 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.81 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sepulveda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.